FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology

Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection. The lack of tumor reference samples along with the associated next generatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan, Kusko, Rebecca, Ning, Baitang, Tong, Weida, Johann, Donald J., Xu, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909622/
https://www.ncbi.nlm.nih.gov/pubmed/35282311
http://dx.doi.org/10.21037/pcm-21-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909622/
https://www.ncbi.nlm.nih.gov/pubmed/35282311
http://dx.doi.org/10.21037/pcm-21-29

Ejemplares similares